Global Equine Healthcare (Diagnostic Products, Therapeutic

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Global Equine Healthcare (Diagnostic Products, Therapeutic Products and Supplement Products) Market Report: Forecasts to 2019

Dublin, July 2, 2014 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/lg...healthcare ) has announced the addition of the "Global Equine Healthcare (Diagnostic Products, Therapeutic Products and Supplement Products) Market Report: Forecasts to 2019 " report to their offering.

The global equestrian market is a multi-billion dollar industry that comprises horse racing and betting, leisure and competitive riding and has spawned and supports multifarious secondary markets. The equine healthcare market ranks as one of the key secondary markets.

This report exclusively studies the market for equine healthcare from varied aspects such as, equine diagnostic products, equine therapeutic products and equine supplement products. It is thus classified into three prime segments namely equine diagnostic products market, equine therapeutic products market and equine supplement products market. The market size and forecast for the period 2013-2019, in terms of USD million, considering 2012 as the base year has been provided for each segment and sub-segments in the report. The compound annual growth rate (CAGR) for each segment and sub-segments has been provided for the forecast period from 2013-2019.

Geographically, the equine healthcare market has been classified into four regions -North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region along with their market growth rate has been highlighted. The market overview section of the report comprises of a qualitative analysis of the market in terms of drivers, restraintsand opportunities, along with market attractiveness analysis.

The report concludes with the competitive landscape and company profiles of few market players in this industry, as of 2012. The market players profiled in this report include Elanco Animal Health, Merck Animal Health, Zoetis (Pfizer Animal Health), Boehringer Ingelheim Vetmedica, Bayer Animal Health, Equine Health U.K., Equine Orthotics and Prosthetics, Affymetrix, Equine Diagnostics, Signostics and Purina.


Scope of the Report

Equine Diagnostic Products Market, by Type

  • Equine Pregnancy and Gestation Diagnostic Products Market
  • Equine UltraSound Devices Market
  • Equine Urine Test Kits Market
  • Equine Genotyping Analysis Products Market
  • Breed Quality Analyzers/Genotype Analyzers Kits Market
  • Genetic Disease Identification Products/Semen Quality Analyzers Market

Equine Therapeutic Products Market, by Type

  • Equine Vaccines Market
  • Equine Antibacterials Market
  • Equine Antivirals Market
  • Equine Antiprotozoals Market
  • Equine Dopamine Agonists Market
  • Equine Anti-inflammatory Drugs Market
  • Equine Laxatives Market

Equine Supplement Products Market, by Type

  • Equine Performance Supplements Market
  • Equine Proteins and Amino Acids Supplements Market
  • Equine Vitamin Supplements Market
  • Equine Electrolyte Supplements Market
  • Other Equine Performance Supplements Market
  • Equine Protection Products Market
  • Equine Protection Products Market
  • Equine Prosthetics Market


Companies Mentioned

  • Affymetrix, Inc.
  • Bayer
  • Boerhringer Ingelheim Vetmedica, Inc. (BIVI)
  • Elanco Animal Health
  • Equine Diagnostics
  • Equine Orthotics and Prosthetics
  • Equine Products (UK) Ltd.
  • Merck Animal Health
  • Purina Mills, LLC
  • Signostics Limited
  • Zoetis, Inc.


For more information visit http://www.researchandmarkets.com/research/lg...healthcare

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Animal Healthcare/Veterinary

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 188

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 384

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 260

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 267

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 392

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 382

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 371

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 472

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 344

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
/news?page=2">More News Articles